scheduled EC meetings (typically monthly or biweekly)

Expedited Review: For minimal-risk studies or minor corrections; usually within 7–10 business days

Exempt Review: Limited to very low-risk studies; timeline depends on EC SOP

Typical duration:

• Submission deadline: 7–14 days before EC meeting
• Review period: 2–6 weeks
• Approval issuance: Within 5 working days post-meeting

To ensure compliance, build EC review planning into your stability studies timelines and clinical trial management plan.

Factors That Affect Initial Review Timelines:

• Document completeness and formatting
• Number of pending submissions in queue
• EC availability and quorum
• Complexity of the protocol (e.g., Phase 1 oncology vs. observational study)
• Presence of vulnerable populations (e.g., pediatric, geriatric)

Submissions using standardized SOPs and templates experience fewer delays.

Ongoing or Continuing Review Timelines:

Ethics Committees are required to perform periodic reviews throughout the trial duration to ensure continued ethical conduct.

• Annual Review: Usually conducted every 12 months from initial approval
• Progress Report Deadline: Submit at least 30 days before expiry of approval
• Report Inclusions: Enrollment status, SAEs, deviations, protocol amendments
• Re-Approval Letter: Issued within 1–3 weeks post-review

Failure to submit on time may result in study suspension until review is completed.

Amendment Review Timeline:

All significant changes to study documents require prior EC approval:

• Submission Timeframe: As soon as changes are finalized
• Review Type: Full board or expedited, depending on change significance
• Approval Duration: 1–3 weeks for expedited, 3–6 weeks for full board

Common amendments include:

• Protocol updates (objectives, arms, design)
• Revised ICFs
• Change in Principal Investigator or trial site
• SAE management updates

Refer to your institution’s GMP documentation process for amendment logs and version tracking.

Site-Specific Review Timelines:

In multicenter studies, EC timelines can vary by site:

• Some sites may use centralized IRBs with faster cycles
• Institutional ECs may follow their unique review calendars
• Investigator Site Files (ISFs) must document all site-specific approvals

Delays at one site should not impact initiation of other EC-approved sites unless using a common central IRB.

Best Practices to Manage Ethics Review Timelines:

• Maintain an EC calendar with submission deadlines and meeting dates
• Track review status using a dedicated CTMS or spreadsheet
• Assign EC coordinator or regulatory affairs lead per site
• Pre-check documents using a submission checklist
• Establish SOPs for EC submissions, amendments, and renewals

Clinical trial professionals should document all EC communications and follow-up timelines in the pharma regulatory compliance tracker.

Ethics Approval Validity Periods:

Initial approvals are generally valid for 1 year from the approval date unless otherwise stated. Continuing reviews must be completed before this validity period ends to ensure:

• Trial remains active and compliant
• Insurance and indemnity coverage are valid
• SAEs are being monitored ethically

For long-term studies, consider staggered renewal plans across sites.

Conclusion:

Understanding and adhering to timelines for initial and ongoing EC reviews is essential for trial continuity and regulatory compliance. Proactive planning, organized documentation, and clear communication with Ethics Committees can help avoid unnecessary delays and audit findings. By embedding these timelines into your project management processes, your clinical trial team ensures ethical oversight and operational efficiency from initiation through close-out.